Aura Biosciences, Inc. (NasdaqGM: AURA)
Health Care · Biotechnology · US
$6.54
0.00% today · +8.5% 1Y
Aura Biosciences, Inc. (NasdaqGM: AURA) operates in the Biotechnology industry within the Health Care sector. The company is valued at $678.23M and employs 113 people.
Over the last twelve months the share price has gained 8.5%, trading between 4.73 and 9.54.
Tweenvest scores Aura Biosciences, Inc. across four factors: quality 45/100, value 73/100. Its strongest factor is value.
AURA price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $678.23M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -1.77
- Dividend yield
- —
- Beta (5Y)
- 0.41
- 52-week high
- $9.54
- 52-week low
- $4.73
- Avg volume (3M)
- —
- Shares outstanding
- 103.70M
- Employees
- 113
- Next earnings
- —
About Aura Biosciences, Inc.
Headquartered in Cambridge, Massachusetts, Aura Biosciences, Inc. is a biotechnology firm established in 2009 that specializes in pioneering cancer treatments. The company leverages its proprietary virus-like drug conjugate (VDC) technology platform to address tumors with significant unmet medical needs, specifically in ocular (eye) and urologic oncology. Its flagship therapeutic candidate, AU-011, is a VDC currently in development for the treatment of primary choroidal melanoma. Furthermore, Aura Biosciences is investigating AU-011's potential for other ocular oncology applications, such as choroidal metastases.
- ISIN
- US05153U1079
- Founded
- 2009
- Listed since
- Oct 29, 2021
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Kexing Biopharm Co., Ltd.SHSE: 688136 | $689.04M | CN¥23.24 | -4.24% |
| Nuvectis Pharma, Inc.NasdaqCM: NVCT | $688.12M | $19.69 | -6.77% |
| Olema Pharmaceuticals, Inc.NasdaqGS: OLMA | $684.23M | $7.36 | -5.88% |
| MiMedx Group, Inc.NasdaqCM: MDXG | $680.70M | $4.83 | +3.43% |
| Qurient Co., Ltd.KOSDAQ: A115180 | $676.80M | ₩22,350.00 | -9.70% |
| Sunmax Biotechnology Co., Ltd.TPEX: 4728 | $674.51M | NT$396.00 | +0.38% |
| Faeth Therapeutics, Inc.NasdaqCM: FTH | $672.63M | $23.25 | -10.68% |
| Abbisko Cayman LimitedSEHK: 2256 | $665.94M | HK$7.89 | -9.83% |
Figures last refreshed Oct 11, 2026.